Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

• Published in: Journal of neurology Vol. 269; no. 2; pp. 824 - 835
• Main Authors: Rauma, Ilkka, Mustonen, Tiina, Seppä, Juha Matti, Ukkonen, Maritta, Männikkö, Marianne, Verkkoniemi-Ahola, Auli, Kartau, Marge, Saarinen, Jukka T., Luostarinen, Liisa, Simula, Sakari, Ryytty, Mervi, Ahmasalo, Riitta, Sipilä, Jussi O. T., Pieninkeroinen, Ilkka, Tapiola, Tero, Remes, Anne M., Kuusisto, Hanna
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022; Springer Nature B.V
• Subjects: Adverse events; Alemtuzumab - adverse effects; Finland - epidemiology; Histiocytosis; Humans; Lymphocytosis; Medicine; Medicine & Public Health; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - epidemiology; Multiple Sclerosis, Relapsing-Remitting; Neurology; Neuroradiology; Neurosciences; Original Communication; Patients; Retrospective Studies; Safety; Thrombocytopenic purpura; Thrombotic thrombocytopenic purpura; Finland; Autoimmunity; Multiple sclerosis; Drug-related side effects and adverse reactions; Alemtuzumab; Safety; Incidence

Background Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods In this retrospective...